12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Zyngenia preclinical data

In a mouse xenograft model of ovarian cancer, Zyngenia's trastuzumab-based bispecific zybody targeting angiopoietin 2 ( ANG2; ANGPT2) and epidermal growth...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >